Study: using Avastin to treat AMD, DME could save Medicare billions
June 9th 2014A study from the University of Michigan, which was recently published in Health Affairs, found that if all eyecare practitioners (ECPs) prescribed Avastin (bevacizumab, Genentech) instead of the more-expensive Lucentis (ranibizumab, Genentech) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), Medicare plans could save $18 billion over a 10-year period.
Study ranks cities with happiest patients
June 5th 2014A study of more than 46,000 online physician reviews finds patients in the San Francisco and Oakland, CA, area are happiest with their health care, while patients in Bakersfield, CA, are the least satisfied with their health care, according to Vanguard Communications.
Valeant bid for Allergan heats up, Pershing plans to replace Allergan board members
June 3rd 2014Allergan says it will “carefully review and consider” a revised proposal from Valeant of $53.8 billion bid-while Pershing Square, the hedge fund that owns 9.7 percent of Allergan is calling to replace the company’s board.
J&J, B+L, Essilor, others fined by Chinese authorities for price fixing
June 3rd 2014Chinese authorities fined Johnson & Johnson, Baush + Lomb, Essilor International, Nikon, and Carl Zeiss Vision Guangzhou a combined total of 19.6 million yuan, or $3 million, for price fixing in the country’s contact lens and eyeglasses market.
Omidria receives FDA approval for use in cataract surgery, IOL replacement
June 3rd 2014The U.S. Food and Drug Administration has approved Omeros’ phenylephrine and ketorolac injection, Omidria, for use during cataract surgery and intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain.
New device aids early AMD diagnosis
May 31st 2014SECO International has a nearly 100-year history of providing optometric meetings of the highest caliber. SECO 2014 was no different. Lectures by our most esteemed colleagues were plentiful, and the knowledge base which was available to attendees was impactful. The exhibit hall provided the opportunity to demo many of the new technologies mentioned in the lectures. One such piece of equipment was AdaptDx by MacuLogix.
3 correction options for presbyopes
May 31st 2014The treatment choices presented to presbyopic patients will depend on many factors, including lifestyle, profession, general attitude toward vision, and levels of disposable income. The first step is ascertaining which two of the three visual acuities are most important to them: near, intermediate, or distance vision. For example, you probably wouldn't recommend a multifocal intraocular lens (IOL) to a professional airline pilot because those lenses may compromise nighttime distance vision.